Myelodysplastic Syndromes: Opportunity Analysis and Forecasts to 2028

1.1 List of Tables
1.2 List of Figures

2.1 Moderate Growth Expected in MDS Market Between 2018 and 2028
2.2 Drug Developers Position Agents to Fill Key Vacancies in the Treatment Paradigms for Higher- and Lower-Risk MDS
2.3 Unmet Needs Persist in Difficult-to-Treat MDS Subgroups, Leaving Substantial Opportunity for Future Players
2.4 Current Late-Stage MDS Pipeline Offers a Range of New Options for Patients in the Front-Line and Later Treatment Settings
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Clinical Presentation and Diagnosis
4.3 Classification
4.3.1 WHO Classification Criteria for MDS
4.3.2 IPSS-R Classification

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for MDS (2018-2028)
5.5.1 Diagnosed Incident Cases of MDS
5.5.2 Age-Specific Diagnosed Incident Cases of MDS
5.5.3 Sex Specific Diagnosed Incident Cases of MDS
5.5.4 Diagnosed Incident Cases of MDS/MPN
5.5.5 Diagnosed Incident Cases of MDS by Subtype
5.5.6 Diagnosed Incident Cases of Primary/Secondary MDS
5.5.7 Diagnosed Incident Cases of MDS by Risk Group
5.5.8 Diagnosed Incident Cases of MDS by Mutations
5.5.9 Five-Year Diagnosed Prevalent Cases of MDS
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

Table 1: Myelodysplastic Syndromes: Key Metrics in the 7MM
Table 2: Common cytogenetic abnormalities in MDS
Table 3: Frequent mutations in MDS
Table 4: Tests used in the Diagnosis of MDS
Table 5: 2016 WHO Classification Criteria for MDS
Table 6: Cytopenia-defining values for MDS
Table 7: IPSS-R Prognostic Risk Categories/Scores and Clinical Outcomes
Table 8: IPSS-R Prognostic Score Values
Table 9: MDS Cytogenetic Scoring System
Table 10: Risk Factors and Comorbidities for MDS
Table 11: Leading Treatments for MDS and Country-Specific Launch Dates, 2020
Table 12: Treatment Guidelines for MDS
Table 13: IWG 2006 Proposed Modified Response Criteria for Altering the Natural History of MDS
Table 14: IWG 2006 Proposed Modified Response Criteria for Hematologic Improvement
Table 15: IWG 2018 Suggested Modified HI-E Criteria for Response Evaluation
Table 16: IWG 2018 Suggested Modified HI-P and HI-N Criteria for Response Evaluation
Table 17: Comparison of Therapies in Development for HR-MDS and LR-MDS, 2018-2028
Table 18: Innovative Early Stage Approaches for MDS, 2020
Table 19: Clinical Benchmark of Key Pipeline Drugs - HR-MDS
Table 20: Clinical Benchmark of Key Pipeline Drugs - HR-MDS
Table 21: Clinical Benchmark of Key Pipeline Drugs - HR-MDS - Allogeneic HSCT
Table 22: Clinical Benchmark of Key Pipeline Drugs - LR-MDS
Table 23: Clinical Benchmark of Key Pipeline Drugs - LR-MDS
Table 24: Commercial Benchmark of Key Pipeline Drugs - HR-MDS
Table 25: Commercial Benchmark of Key Pipeline Drugs - HR-MDS
Table 26: Commercial Benchmark of Key Pipeline Drugs - HR-MDS -HSCT
Table 27: Commercial Benchmark of Key Pipeline Drugs - LR-MDS
Table 28: Commercial Benchmark of Key Pipeline Drugs - LR-MDS
Table 29: MDS Market - Global Drivers and Barriers, 2018-2028
Table 30: Key Events Impacting Sales for MDS in the US, 2018-2028
Table 31: Key Events Impacting Sales for MDS in the 5EU, 2018-2028
Table 32: Key Events Impacting Sales for MDS in Japan, 2018-2028
Table 33: Key Historical and Projected Launch Dates for MDS
Table 34: Key Historical and Projected Patent/Exclusivity Expiry Dates for MDS
Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for MDS in 2018 and 2028
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, HR-MDS
Figure 3: Competitive Assessment of Omidubicel Against the Standard of Care, HR-MDS
Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, LR-MDS
Figure 5: Key Therapeutic Mechanisms in MDS
Figure 6: 8MM, Diagnosed Incidence Rates of MDS, Men and Women, Ages =18 Years, Cases per 100,000 Population, 2008?2028
Figure 7: Sources Used for Diagnosed Incident Cases of MDS
Figure 8: Sources Used for Diagnosed Incident Cases of MDS/MPN
Figure 9: Sources Used for Diagnosed Incident Cases of MDS Subtypes
Figure 10: Sources Used for Diagnosed Incident Cases of Primary/Secondary MDS
Figure 11: Sources Used for Five-Year Diagnosed Prevalent Cases of MDS
Figure 12: 8MM, Diagnosed Incident Cases of MDS, Men and Women, Ages =18 Years, N, 2018
Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of MDS, Men and Women, Ages =18 Years, N, 2018
Figure 14: 8MM, Sex-Specific Diagnosed Incident Cases of MDS, Men and Women, Ages =18 Years, N, 2018
Figure 15: 8MM, Diagnosed Incident Cases MDS/MPN, Men and Women, Ages =18 Years, N, 2018
Figure 16: 8MM, Proportion of Diagnosed Incident Cases of MDS by Subtype, Men and Women, Ages =18 Years, N, 2018
Figure 17: 8MM, Proportion of Diagnosed Incident Cases of Primary/Secondary MDS, Men and Women, Ages =18 Years, 2018
Figure 18: 8MM, Diagnosed Incident Cases of MDS by Risk Group, Men and Women, Ages =18 Years, N, 2018
Figure 19: 8MM, Diagnosed Incident Cases of MDS by Mutation, Men and Women, Ages =18 Years, N, 2018
Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of MDS, Men and Women, Ages =18 Years, N, 2018
Figure 21: NCCN Treatment Flow for HR-MDS
Figure 22: NCCN Treatment Flow for LR-MDS
Figure 23: Unmet Needs and Opportunities in MDS
Figure 24: Overview of the Development Pipeline in MDS
Figure 25: Key Phase II/III Trials for Promising Pipeline Agents that the Publisher Expects be Licensed for MDS in the 7MM During the Forecast Period
Figure 26:Competitive Assessment of Marketed and Pipeline Drugs Benchmarked Against the SOC, HR-MDS
Figure 27:Competitive Assessment of Omidubicel Against the SOC, HR-MDS
Figure 28:Competitive Assessment of Marketed and Pipeline Drugs Benchmarked Against the SOC, LR-MDS
Figure 29: Global Sales Forecast by Country for MDS in 2018 and 2028
Figure 30: Global MDS Sales Forecast by Class, 2018 and 2028
Figure 31: US MDS Sales Forecast by Class, 2018 and 2028
Figure 32: 5EU MDS Sales Forecast by Class, 2018 and 2028
Figure 33: Japan MDS Sales Forecast by Class, 2018 and 2028